EA201890900A1 - Пептиды - Google Patents

Пептиды

Info

Publication number
EA201890900A1
EA201890900A1 EA201890900A EA201890900A EA201890900A1 EA 201890900 A1 EA201890900 A1 EA 201890900A1 EA 201890900 A EA201890900 A EA 201890900A EA 201890900 A EA201890900 A EA 201890900A EA 201890900 A1 EA201890900 A1 EA 201890900A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
amino acids
side chain
missing
absent
Prior art date
Application number
EA201890900A
Other languages
English (en)
Russian (ru)
Inventor
Ричард Морган
Original Assignee
Хокс Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хокс Терапьютикс Лимитед filed Critical Хокс Терапьютикс Лимитед
Publication of EA201890900A1 publication Critical patent/EA201890900A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
EA201890900A 2015-10-21 2016-10-20 Пептиды EA201890900A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1518700.8A GB2543550A (en) 2015-10-21 2015-10-21 Peptides
PCT/GB2016/053282 WO2017068353A1 (en) 2015-10-21 2016-10-20 Peptides

Publications (1)

Publication Number Publication Date
EA201890900A1 true EA201890900A1 (ru) 2018-10-31

Family

ID=55131441

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890900A EA201890900A1 (ru) 2015-10-21 2016-10-20 Пептиды

Country Status (13)

Country Link
US (1) US10494412B2 (enExample)
EP (2) EP3364992B1 (enExample)
JP (1) JP2018533570A (enExample)
KR (1) KR20180080217A (enExample)
CN (1) CN108430491A (enExample)
AU (1) AU2016341494A1 (enExample)
BR (1) BR112018008136A2 (enExample)
CA (1) CA3002739A1 (enExample)
EA (1) EA201890900A1 (enExample)
ES (1) ES2775740T3 (enExample)
GB (1) GB2543550A (enExample)
MX (1) MX2018004930A (enExample)
WO (1) WO2017068353A1 (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
ES2236703T3 (es) * 1994-01-14 2005-07-16 Matthias Dr Med Rath Uso de metodos para identificar oligopeptidos de señal hidrofilos.
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6573293B2 (en) 2000-02-15 2003-06-03 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
GB0229151D0 (en) * 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20050148627A1 (en) 2003-03-31 2005-07-07 Jeffery Carter Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
US7259266B2 (en) 2003-03-31 2007-08-21 Pharmacia Corporation Benzopyran compounds useful for treating inflammatory conditions
JP2009500314A (ja) * 2005-06-29 2009-01-08 セント ジョージス エンタープライシス リミテッド 遺伝子調節
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
ES2633453T3 (es) * 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
CN108430491A (zh) 2018-08-21
AU2016341494A1 (en) 2018-05-24
ES2775740T3 (es) 2020-07-28
GB2543550A (en) 2017-04-26
WO2017068353A1 (en) 2017-04-27
MX2018004930A (es) 2018-11-09
EP3364992B1 (en) 2019-12-04
US10494412B2 (en) 2019-12-03
EP3364992A1 (en) 2018-08-29
CA3002739A1 (en) 2017-04-27
BR112018008136A2 (pt) 2018-11-06
GB201518700D0 (en) 2015-12-02
ES2775740T8 (es) 2020-08-06
US20180282384A1 (en) 2018-10-04
EP3610883A1 (en) 2020-02-19
JP2018533570A (ja) 2018-11-15
KR20180080217A (ko) 2018-07-11

Similar Documents

Publication Publication Date Title
SA518400623B1 (ar) جينات ديستروفين صغير محسنة ومجموعات إظهارها واستخدامها
EA202090817A1 (ru) Триспецифические белки и способы их применения
PE20191206A1 (es) Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y trastornos musculares
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
PE20191136A1 (es) Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
MX2013012791A (es) Analogos del factor b del complemento y sus usos.
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
EA202191208A1 (ru) ВЕКТОРЫ, СОДЕРЖАЩИЕ AIMP2-DX2 И ЦЕЛЕВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ ДЛЯ miR-142, И ИХ ПРИМЕНЕНИЕ
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
PH12017550134A1 (en) Il-37 variants
MX2017010259A (es) Proteina resistente a herbicidas, gen codificante y uso de los mismos.
PH12021551428A1 (en) Recombinant avian herpes viruses containing multiple foreign genes
EA202190888A1 (ru) Пептид для применения в косметике
CY1123916T1 (el) Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
PH12017502323B1 (en) Novel xylanase
EA201890900A1 (ru) Пептиды
BR112017011108A2 (pt) composições de cabelo contendo polímeros catiônicos
PH12019501164A1 (en) Trehalose phosphorylase
WO2014204229A3 (ko) 펩타이드를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 약학적 조성물